Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03028103 |
| Title | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Epizyme, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | United States | Details | |
| Moffitt Cancer Center | Tampa | Florida | 33612 | United States | Details | |
| Columbia University Medical Center | New York | New York | 10032 | United States | Details |